CBDMD INC (YCBD) Stock Fundamental Analysis
USA - NYSEARCA:YCBD - US12482W4087 - Common Stock
0.79 USD
-0.01 (-1.25%)
Taking everything into account, YCBD scores 2 out of 10 in our fundamental rating. YCBD was compared to 191 industry peers in the Pharmaceuticals industry. While YCBD seems to be doing ok healthwise, there are quite some concerns on its profitability. YCBD is valued expensive and it does not seem to be growing.
1. Profitability
1.1 Basic Checks
In the past year YCBD has reported negative net income.
YCBD had a negative operating cash flow in the past year.
In the past 5 years YCBD reported 4 times negative net income.
YCBD had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
The Return On Assets of YCBD (-49.02%) is comparable to the rest of the industry.
With a Return On Equity value of -79.38%, YCBD perfoms like the industry average, outperforming 45.55% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -49.02% | ||
| ROE | -79.38% | ||
| ROIC | N/A |
ROA(3y)-140.25%
ROA(5y)-86.1%
ROE(3y)-308.88%
ROE(5y)-187.27%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
YCBD's Gross Margin of 61.20% is fine compared to the rest of the industry. YCBD outperforms 71.20% of its industry peers.
In the last couple of years the Gross Margin of YCBD has remained more or less at the same level.
YCBD does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 61.2% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.98%
GM growth 5Y0.07%
2. Health
2.1 Basic Checks
YCBD does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for YCBD has been increased compared to 1 year ago.
The number of shares outstanding for YCBD has been increased compared to 5 years ago.
The debt/assets ratio for YCBD is higher compared to a year ago.
2.2 Solvency
Based on the Altman-Z score of -22.63, we must say that YCBD is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -22.63, YCBD is not doing good in the industry: 83.77% of the companies in the same industry are doing better.
YCBD has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -22.63 |
ROIC/WACCN/A
WACC8.83%
2.3 Liquidity
A Current Ratio of 1.56 indicates that YCBD should not have too much problems paying its short term obligations.
YCBD has a worse Current ratio (1.56) than 68.06% of its industry peers.
YCBD has a Quick Ratio of 1.56. This is a bad value and indicates that YCBD is not financially healthy enough and could expect problems in meeting its short term obligations.
YCBD has a worse Quick ratio (0.78) than 82.20% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.56 | ||
| Quick Ratio | 0.78 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 71.77% over the past year.
The Revenue has decreased by -7.80% in the past year.
The Revenue has been decreasing by -3.80% on average over the past years.
EPS 1Y (TTM)71.77%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-132.81%
Revenue 1Y (TTM)-7.8%
Revenue growth 3Y-24.06%
Revenue growth 5Y-3.8%
Sales Q2Q%-10.96%
3.2 Future
Based on estimates for the next years, YCBD will show a very strong growth in Earnings Per Share. The EPS will grow by 40.90% on average per year.
Based on estimates for the next years, YCBD will show a small growth in Revenue. The Revenue will grow by 0.98% on average per year.
EPS Next Y92.04%
EPS Next 2Y40.9%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-2.84%
Revenue Next 2Y0.98%
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for YCBD. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for YCBD. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as YCBD's earnings are expected to grow with 40.90% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y40.9%
EPS Next 3YN/A
5. Dividend
5.1 Amount
YCBD does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NYSEARCA:YCBD (11/12/2025, 9:30:59 AM)
0.79
-0.01 (-1.25%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners5.44%
Inst Owner Change3.34%
Ins Owners1.71%
Ins Owner Change0.93%
Market Cap7.04M
Revenue(TTM)19.03M
Net Income(TTM)-4.85M
Analysts82.86
Price Target2.04 (158.23%)
Short Float %5.33%
Short Ratio0.09
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly Dividend0
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-472.92%
Min EPS beat(2)-929.41%
Max EPS beat(2)-16.42%
EPS beat(4)2
Avg EPS beat(4)-215.74%
Min EPS beat(4)-929.41%
Max EPS beat(4)41.71%
EPS beat(8)4
Avg EPS beat(8)-101.11%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-12.14%
Min Revenue beat(2)-14.83%
Max Revenue beat(2)-9.45%
Revenue beat(4)0
Avg Revenue beat(4)-8.67%
Min Revenue beat(4)-14.83%
Max Revenue beat(4)-3.36%
Revenue beat(8)1
Avg Revenue beat(8)-8.77%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-33.33%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-250%
EPS NY rev (1m)0%
EPS NY rev (3m)72.45%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-12.91%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-6.77%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 0.37 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 1.15 | ||
| P/tB | 1.85 | ||
| EV/EBITDA | N/A |
EPS(TTM)-6.03
EYN/A
EPS(NY)-0.2
Fwd EYN/A
FCF(TTM)-0.15
FCFYN/A
OCF(TTM)-0.12
OCFYN/A
SpS2.14
BVpS0.69
TBVpS0.43
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -49.02% | ||
| ROE | -79.38% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 61.2% | ||
| FCFM | N/A |
ROA(3y)-140.25%
ROA(5y)-86.1%
ROE(3y)-308.88%
ROE(5y)-187.27%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.98%
GM growth 5Y0.07%
F-Score5
Asset Turnover1.92
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 25.3% | ||
| Cap/Sales | 1.53% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.56 | ||
| Quick Ratio | 0.78 | ||
| Altman-Z | -22.63 |
F-Score5
WACC8.83%
ROIC/WACCN/A
Cap/Depr(3y)26.48%
Cap/Depr(5y)59.22%
Cap/Sales(3y)1.56%
Cap/Sales(5y)1.72%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)71.77%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-132.81%
EPS Next Y92.04%
EPS Next 2Y40.9%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-7.8%
Revenue growth 3Y-24.06%
Revenue growth 5Y-3.8%
Sales Q2Q%-10.96%
Revenue Next Year-2.84%
Revenue Next 2Y0.98%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y64.11%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y77.96%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y82.51%
OCF growth 3YN/A
OCF growth 5YN/A
CBDMD INC / YCBD FAQ
What is the ChartMill fundamental rating of CBDMD INC (YCBD) stock?
ChartMill assigns a fundamental rating of 2 / 10 to YCBD.
What is the valuation status for YCBD stock?
ChartMill assigns a valuation rating of 1 / 10 to CBDMD INC (YCBD). This can be considered as Overvalued.
How profitable is CBDMD INC (YCBD) stock?
CBDMD INC (YCBD) has a profitability rating of 1 / 10.
Can you provide the dividend sustainability for YCBD stock?
The dividend rating of CBDMD INC (YCBD) is 0 / 10 and the dividend payout ratio is 0%.